Published in Aliment Pharmacol Ther on February 01, 2002
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 4.66
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut (2007) 3.15
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int (2014) 2.56
Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ (2003) 2.04
Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol (2003) 1.60
Recent developments in gastroenterology. BMJ (2002) 1.59
Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut (2004) 1.55
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol (2004) 1.33
Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother (2002) 1.27
Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ (2015) 1.24
Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther (2015) 1.22
Eradication of Helicobacter pylori: a clinical update. MedGenMed (2004) 1.20
Best practice in primary care pathology: review 1. J Clin Pathol (2005) 1.18
Helicobacter pylori and antibiotic resistance. Gut (2007) 1.17
Test and treat for dyspepsia--but which test? BMJ (2005) 1.12
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol (2007) 1.10
Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract (2012) 1.10
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr (2010) 1.10
Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol (2007) 1.10
A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol (2014) 1.09
Are dyspeptic symptoms linked to Helicobacter pylori? A prospective cohort study among medical students. Wien Klin Wochenschr (2003) 1.08
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol (2004) 1.07
Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother (2006) 1.07
Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol (2006) 1.07
Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer (2009) 1.06
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver (2015) 1.04
Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol (2004) 1.03
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol (2013) 1.03
Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond. Br J Clin Pharmacol (2004) 1.03
Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol (2014) 1.03
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr (2009) 1.02
Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol (2006) 1.02
Comparison of three stool antigen tests for Helicobacter pylori detection. J Clin Pathol (2003) 1.02
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol (2010) 1.01
Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut (2006) 1.00
Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol (2014) 0.99
"Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol (2008) 0.99
Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice. Clin Diagn Lab Immunol (2005) 0.98
A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol (2007) 0.98
The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can J Gastroenterol (2006) 0.98
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol (2005) 0.97
Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol (2008) 0.97
Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Serv Res (2010) 0.96
Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol (2012) 0.96
Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol (2014) 0.96
Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol (2014) 0.96
Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci (2007) 0.96
Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol (2014) 0.96
Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. Iran J Pediatr (2013) 0.96
Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci (2014) 0.95
Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World J Gastroenterol (2005) 0.95
Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer. World J Gastroenterol (2002) 0.94
Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr (2012) 0.94
Evaluation of the stool antigen test for Helicobacter pylori in children and adolescents. Dig Dis Sci (2005) 0.93
Diet, H pylori infection and gastric cancer: evidence and controversies. World J Gastroenterol (2007) 0.93
Dyspepsia: management guidelines for the millennium. Gut (2002) 0.93
Evaluation of a novel rapid one-step immunochromatographic assay for detection of monoclonal Helicobacter pylori antigen in stool samples from children. J Clin Microbiol (2005) 0.92
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr (2007) 0.92
The relationship between virulence factors of Helicobacter pylori and severity of gastritis in infected patients. Dig Dis Sci (2008) 0.91
Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect (2006) 0.91
Causes of failure of eradication of Helicobacter pylori. BMJ (2002) 0.91
Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol (2013) 0.90
Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol (2004) 0.90
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. World J Gastroenterol (2005) 0.89
Evaluation and management of dyspepsia. Therap Adv Gastroenterol (2010) 0.89
Sensitivity of a novel stool antigen test for detection of Helicobacter pylori in adult outpatients before and after eradication therapy. J Clin Microbiol (2004) 0.89
Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob (2010) 0.89
Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.89
Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial. Gut (2005) 0.88
Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol (2010) 0.88
Shift work increases the frequency of duodenal ulcer in H pylori infected workers. Occup Environ Med (2006) 0.88
Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut (2003) 0.88
Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol (2009) 0.87
Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract (2012) 0.87
Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract (2012) 0.87
Role of Helicobacter pylori in functional dyspepsia. World J Gastroenterol (2006) 0.87
Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in Helicobacter pylori-positive Turkish patients with dyspepsia. J Gastroenterol (2008) 0.87
Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr Infect Dis Rep (2005) 0.86
The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther (2013) 0.86
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci (2011) 0.86
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr (2009) 0.86
Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrob Agents Chemother (2005) 0.85
Helicobacter pylori stool antigen assay in hyperemesis gravidarum: a risk factor for hyperemesis gravidarum or not? Dig Dis Sci (2007) 0.85
Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol (2005) 0.85
Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J Clin Microbiol (2003) 0.85
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol (2016) 0.85
Treatment of uncomplicated reflux disease. World J Gastroenterol (2005) 0.85
Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the ¹³C-Urea breath test. BMC Public Health (2013) 0.84
Survey of general practitioners' knowledge about Helicobacter pylori infection. BMC Gastroenterol (2005) 0.84
Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Ther Clin Risk Manag (2007) 0.84
Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol (2012) 0.84
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol (2008) 0.84
ALSPAC--the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol (2001) 14.31
Implementing findings of research. BMJ (1994) 12.85
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Is the two week rule for cancer referrals working? BMJ (2001) 7.90
Restriction endonucleases for pulsed field mapping of bacterial genomes. Nucleic Acids Res (1987) 7.03
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
It's not 'just deprivation': why do equally deprived UK cities experience different health outcomes? Public Health (2010) 6.65
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
Norwalk virus genome cloning and characterization. Science (1990) 5.83
Qualitative research methods in general practice and primary care. Fam Pract (1995) 5.72
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Assessment of clinical competence. Lancet (2001) 5.21
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet (1995) 5.14
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Proteolytic enhancement of rotavirus infectivity: molecular mechanisms. J Virol (1981) 4.87
Does continuing medical education in general practice make a difference? BMJ (1999) 4.40
In vitro transcription and translation of simian rotavirus SA11 gene products. J Virol (1980) 4.40
Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet (1987) 4.32
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Gene coding assignments for growth restriction, neutralization and subgroup specificities of the W and DS-1 strains of human rotavirus. J Gen Virol (1983) 4.25
Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol (1999) 4.13
Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology (1998) 4.12
Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med (1994) 4.09
New ages for the last Australian megafauna: continent-wide extinction about 46,000 years ago. Science (2001) 3.91
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol (1992) 3.82
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A (2000) 3.66
Consent and confidentiality in teaching in general practice: survey of patients' views on presence of students. BMJ (1997) 3.64
Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol (1996) 3.57
Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model. J Clin Microbiol (1997) 3.57
p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J (1991) 3.55
Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract (1989) 3.53
Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology (1999) 3.37
A study of general practitioners' reasons for changing their prescribing behaviour. BMJ (1996) 3.36
The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33
Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol (1996) 3.32
Variants of the 3' region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol (1998) 3.31
Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother (1997) 3.27
Why do qualitative research? BMJ (1995) 3.23
Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections. J Virol (1988) 3.20
Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol (1996) 3.20
Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16
N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen. Infect Immun (1988) 3.16
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet (1991) 3.09
Lead-contaminated soil abatement and urban children's blood lead levels. JAMA (1993) 3.06
Rescue and serotypic characterization of noncultivable human rotavirus by gene reassortment. Infect Immun (1982) 2.97
Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol (1993) 2.96
Ultrastructural localization of rotavirus antigens using colloidal gold. Virus Res (1984) 2.95
Recognition of faux pas by normally developing children and children with Asperger syndrome or high-functioning autism. J Autism Dev Disord (1999) 2.90
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology (1992) 2.83
Mental health care training priorities in general practice. Br J Gen Pract (1997) 2.79
Why do early-emerging tree seedlings have survival advantages?: a test using Acer rubrum (Aceraceae). Am J Bot (1997) 2.77
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci (1995) 2.75
Identification, synthesis, and modifications of simian rotavirus SA11 polypeptides in infected cells. J Virol (1982) 2.67
A plaque assay for the simian rotavirus SAII. J Gen Virol (1979) 2.65
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63
Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation (1991) 2.62
General practitioners with special clinical interests. Clin Med (2001) 2.61
Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology (1982) 2.60
Evaluation of filter paper blood lead methods: results of a pilot proficiency testing program. Clin Chem (1999) 2.58
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Rotavirus stability and inactivation. J Gen Virol (1979) 2.48
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother (1997) 2.47
Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med (1994) 2.47
Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology (1999) 2.44
Patients, payers, and paradigm shifts: what to do about Helicobacter pylori. Am J Gastroenterol (1996) 2.43
Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter (1998) 2.39
Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis (1998) 2.38
Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol (1997) 2.37
Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc (1994) 2.36
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab (2013) 2.31
Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med (1984) 2.29
The early detection of colorectal cancer in primary care. Br J Gen Pract (1999) 2.26
Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother (1986) 2.26
Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology (1983) 2.23
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ (1998) 2.21
Selection of the T cell repertoire. Annu Rev Immunol (1999) 2.21
Managing acute renal colic across the primary-secondary care interface: a pathway of care based on evidence and consensus. BMJ (2002) 2.20
Open access endoscopy. Br Med J (Clin Res Ed) (1985) 2.18
Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol (1994) 2.16
Helicobacter pylori: the cancer link. J R Soc Med (1996) 2.15
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut (1994) 2.14
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut (1990) 2.13
Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive behavior therapy. Arch Gen Psychiatry (1993) 2.12
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Rectal bleeding: prevalence and consultation behaviour. BMJ (1995) 2.11
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10